← All trials
NCT01176565
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 15, 2011
- Primary completion
- Dec 21, 2015
- Completion date
- Mar 8, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 1000
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of MinnesotaLead sponsor
- University of MinnesotaOverall official - principal investigator
- Medical University of South CarolinaOverall official - principal investigator
- University of MinnesotaStudy chair
- Medical University of South CarolinaStudy director
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- Johns Hopkins UniversityCollaborator
- University of MichiganCollaborator
- National Cerebral and Cardiovascular CenterCollaborator
- Japan Cardiovascular Research FoundationCollaborator
- Capital Medical UniversityCollaborator
- Seoul National UniversityCollaborator
- Medical University of South CarolinaCollaborator
- China Medical UniversityCollaborator
- University of HeidelbergCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.